Sable Bio Limited
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Sable Bio Limited - overview
Established
2023
Location
London, -, UK
Primary Industry
Software
About
Based in London, UK, and founded in 2023, Sable Bio Limited, also known as Sable, operates as an AI-enabled drug discovery company. The company was founded by Josh Almond-Thynne and Alex de Giorgio. In February 2026, Sable Bio Limited raised GBP 2. 7 million in seed funding.
Sable provides B2B (business-to-business) software solutions for biotech and pharma companies. The company’s product includes a drug discovery platform that uses artificial intelligence and large language models to analyze structured and unstructured data sources from multiple sources, including clinical trials, for personalized drug predictions and safety assessments. The company plans to use the funds raised in February 2024 to enhance its fundamental technology infrastructure and its robust and extensive data capabilities.
Current Investors
Seedcamp, Episode 1 Ventures, MMC Ventures
Primary Industry
Software
Sub Industries
Biotechnology, Medical Software
Website
www.sablebio.com
Verticals
Artificial Intelligence, Cloud Computing, HealthTech
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.